Circulogene Theranostics Accepts First International Orders For Cell-Free DNA Liquid Biopsy Testing

Single-blood-drop, high-yield DNA testing drives international demand for Circulogene’s fast, accurate, cancer monitoring and treatment products

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Circulogene Theranostics, the only biotechnology company able to enrich circulating cell-free DNA (cfDNA) from a single blood drop for patient-specific monitoring of cancer, has received the first international orders for its liquid biopsy testing products from Turkey, Hungary and Israel. The news comes less than three months after the company formally launched its cfDNA tumor detection and monitoring products, which enable fast, accurate and personalized testing of 10 tumor types, including breast, lung and colon cancer.

“In addition to growing demand here in the U.S., other countries and governmental organizations see tremendous value in blood-drop-volume samples that deliver maximum output from minimum input.”

“Our single-blood-drop value proposition has gained significant international attention,” said Circulogene Chief Commercial Officer James Straza. “In addition to growing demand here in the U.S., other countries and governmental organizations see tremendous value in blood-drop-volume samples that deliver maximum output from minimum input.”

Non-invasive liquid biopsies represent a major advance over traditional surgical tumor biopsies, which are costly, time consuming and only sample a small portion of tumor tissue, leading to a high failure rate. However, even current industry-standard liquid biopsy methods require large sample amounts, and DNA loss from the extraction process can miss critical tumor information, which can significantly change a patient’s treatment and prognosis.

“We’re particularly interested in Circulogene’s proprietary DNA enrichment capabilities, because it results in near-full recovery of cfDNA from finger-stick volumes of blood,” said Ati Goknur, COO of GGT Global Genetik, which is distributing in Turkey. “The small-volume blood samples are easily shipped, and we’re able to gain a wealth of DNA information, giving our medical experts in Istanbul, as well as the rest of Turkey, the most accurate testing and personalized cancer management capabilities available in the market today.”

The company’s proprietary method can collect more than 100 times more cfDNA with just 1/10 of the blood (as little as 20 microliters) compared to the current industry standard for non-invasive liquid biopsy testing. Circulogene’s liquid biopsy testing is capable of detecting nearly 3000 cancer mutations on 50 well-established cancer-associated genes for its 10 cancer profiles.

Once cancer has been diagnosed in a patient, Circulogene’s laboratory can report testing results back to physicians in a matter of days to aid them in selecting the right therapy at the right time for each patient’s unique situation.

Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified, and it plans to expand research initiatives to independently demonstrate greatly increased sensitivity and specificity compared to current methods. For more information, visit our website, connect with us on LinkedIn, email us at info@circulogene.com or call 205-278-1600. Clinicians interested in ordering the test may visit the Contact page on Circulogene’s website.

About Circulogene Theranostics

Headquartered in Birmingham, Ala., Circulogene Theranostics is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA liquid biopsies, Circulogene has developed the first droplet-volume, next-generation sequencing (NGS) method to provide full genomic load analysis, enabling more accurate data to help clinicians and their patients. For more information, visit www.circulogene.com or call 205-278-1600.